Research programme: gene editing therapeutics - Reforgene medicine
Alternative Names: in vivo gene editing; in-vivo gene therapyLatest Information Update: 03 Mar 2023
At a glance
- Originator Reforgene Medicine
- Class Antineoplastics; Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Unspecified
Most Recent Events
- 23 Dec 2022 Early research in Cancer in China (Parenteral)(Reforgene medicine pipeline, December 2022)
- 23 Dec 2022 Early research in Unspecified in China (Parenteral)(Reforgene medicine pipeline, December 2022)